(Q41749204)

8 October 2017

1 reference

title

Metformin: effects on cardiovascular risk factors in patients with non-insulin-dependent diabetes mellitus (English)

1 reference

8 October 2017

1 reference

Palumbo PJ

1

1 reference

8 October 2017

1 March 1998

1 reference

Journal of Diabetes and its Complications

8 October 2017

1 reference

8 October 2017

12

1 reference

8 October 2017

2

1 reference

8 October 2017

110-119

1 reference

Type II Diabetes and Syndrome X: Pathogenesis and Glycemic Management

8 October 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900053-6

7 January 2021

Banting lecture 1988. Role of insulin resistance in human disease

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900053-6

7 January 2021

Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900053-6

7 January 2021

Pathophysiology of diabetes. A review of selected recent developments and their impact on treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900053-6

7 January 2021

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900053-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900053-6

1 reference

7 January 2021

New orally administered antihyperglycemic agents for the management of patients with type ii diabetes and the syndrome of insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900053-6

7 January 2021

Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900053-6

7 January 2021

Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900053-6

7 January 2021

Type 2 (non-insulin-dependent) diabetes mellitus and coronary heart disease ? chicken, egg or neither?

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900053-6

7 January 2021

Evidence that multiple risk factors for coronary artery disease exist in persons with abnormal glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900053-6

7 January 2021

Incidence and prevalence of clinical peripheral vascular disease in a population-based cohort of diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900053-6

7 January 2021

Progression of peripheral occlusive arterial disease in diabetes mellitus. What factors are predictive?

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900053-6

7 January 2021

Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900053-6

7 January 2021

Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900053-6

7 January 2021

Impaired fibrinolysis in coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900053-6

7 January 2021

Tissue plasminogen activator activity and inhibition in acute myocardial infarction and angiographically normal coronary arteries

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900053-6

7 January 2021

Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900053-6

7 January 2021

Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900053-6

7 January 2021

Plasminogen activator inhibitor-1 synthesis in the human hepatoma cell line Hep G2. Metformin inhibits the stimulating effect of insulin

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900053-6

7 January 2021

Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900053-6

7 January 2021

Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900053-6

7 January 2021

Cholesterol Lowering Effect of Metformin in Combined Hyperlipidemia: Placebo Controlled Double Blind Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900053-6

7 January 2021

Metabolic and hemodynamic effects of metformin and glibenclamide in normotensive NIDDM patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900053-6

7 January 2021

Effect of metformin on postprandial lipemia in patients with fairly to poorly controlled NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900053-6

7 January 2021

Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900053-6

7 January 2021

The effect of glibenclamide and metformin on serum lipoproteins in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900053-6

7 January 2021

Combined metformin-sulfonylurea treatment of patients with noninsulin-dependent diabetes in fair to poor glycemic control

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900053-6

7 January 2021

Metabolic effects of metformin in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900053-6

7 January 2021

Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900053-6

7 January 2021

Treatment of hypertriglyceridemia with metformin. Effectiveness and analỳsis of results

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900053-6

7 January 2021

Lipoprotein patterns in diet, sulphonylurea, and insulin treated diabetics.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900053-6

7 January 2021

Relation of high-density lipoprotein cholesterol concentration to type of diabetes and its control

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900053-6

7 January 2021

Comparison of tolbutamide and metformin in elderly diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900053-6

7 January 2021

Comparison of chlorpropamide and metformin treatment on weight and blood-glucose response of uncontrolled obese diabetics

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900053-6

7 January 2021

Comparison of metformin and chlorpropamide in non-obese, maturity-onset diabetics uncontrolled by diet

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900053-6

7 January 2021

Double-blind evaluation of efficacy and tolerability of metformin in NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900053-6

7 January 2021

Metformin and blood pressure

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900053-6

7 January 2021

Metformin reduces platelet hypersensitivity in hypercholesterolemic rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900053-6

7 January 2021

Study of the effect of metformin on platelet aggregation in insulin-dependent diabetics

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900053-6

7 January 2021

Metformin Causes a Reduction in Basal and Post-venous Occlusion Plasminogen Activator Inhibitor-1 in Type 2 Diabetic Patients

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900053-6

7 January 2021

Metformin improves peripheral vascular flow in nonhyperlipidemic patients with arterial disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900053-6

7 January 2021

10.1016/S1056-8727(97)00053-6

Identifiers

DOI

1 reference

8 October 2017

1 reference

PubMed ID

9559489